A Prospective Randomized Comparison of HDAC Vs AD in the Induction Chemothrapy for AML.

NCT03507842 · clinicaltrials.gov ↗

PHASE3

Phase

ENROLLING_BY_INVITATION

Status

380

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: High dose Cytarabine
DRUG: Cytarabine
DRUG: Hign dose Daunorubicin

Sponsor

Asan Medical Center